VIR logo

VIR Vir Biotechnology, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$8.39
-0.48 (-5.41%)

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3…

Market Cap: $1.44Bwww.vir.bio

Price

No data yet.

Social Signal Score

57
5d
—
30d
58
9 mentions
—
60d
56
11 mentions
—
90d
56
11 mentions
—
news: 11

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 2Sell 0Strong Sell 0
Avg price target$23.5+180.1%
Low $22Median $23.5High $25
Current Consensus

Revenue

$-188.0K-108.07%
$-40.63M$383.73M$808.10M$1.23B
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-3.35
$-3.75–$-3.03
7 analysts
FY2026
$-1.06
$-1.45–$-0.74
6 analysts
FY2027
$-2.34
$-2.92–$-2.00
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marianne De Backer
Sector
Healthcare
Industry
Biotechnology
Employees
367
Beta
1.70
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
2.44
www.vir.bio